During a presentation in Taipei on Monday the CEO of US therapeutics company Receptor BioLogix Dr. Michael Shepard outlined his company's anti-cancer drug development pipeline.
Shepard's talk focused on the company's new drug Herstatin designed to act on tumor cells that overexpress HERS-2—human epidermal growth factor receptor 2. At this early stage of drug testing Herstatin is showing effectiveness on a wider range of cancers than the earlier-generation anti-cancer HERS-2 drug Herceptin co-discovered by Shepard and now produced by US-based Genentech mainly for breast cancer treatment. |
All times are GMT -7. The time now is 06:46 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021